Chinese scientists announced the successful completion of the third phase of clinical trials for a new drug. This drug is a humanized monoclonal antibody targeting interleukins-17A/F and is intended for the treatment of patients with ankylosing spondylitis, known as Bechterew's disease.
According to the trial results, a significant number of participants who took the active substance demonstrated a substantial improvement in their health condition. These indicators were significantly higher than those in the placebo group.
A detailed report on the conducted studies was officially published in the scientific journal hLife.